Yeah, I just read this on the annual report
Seqirus sales of US$652 million reflect 11 months of sales since
the acquisition of Novartis’ influenza vaccines business on 31
July 2015. Sales of influenza vaccine were adversely impacted by
a mild influenza season in the northern hemisphere. The Seqirus
business turnaround program remains on track.
CSL Decline, page-35
-
- There are more pages in this discussion • 158 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$295.00 |
Change
0.000(0.00%) |
Mkt cap ! $142.8B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $312.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $235.99 | 38 | 2 |
View Market Depth
| Last trade - 10.00am 10/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |
Day chart unavailable